At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2, Dose Escalation and Expansion Study of BGB-10188, a Phosphatidylinositol 3-Kinase Delta (PI3Kδ) Inhibitor, Combined With Zanubrutinib in Patients With Mature B-Cell Malignancies and Combined With Tislelizumab in Patients With Solid Tumors
In Brief
A Phase 2 clinical trial evaluating BGB-10188, Zanubrutinib, and 1 other intervention for Chronic Lymphocytic Leukemia and 6 related conditions. Completed, enrolled 97 participants across 24 sites in 2 countries.
Detailed Summary
The purpose of this study was to determine the maximum tolerated dose (MTD), recommended dose for expansion (RDFE), safety and tolerability of BGB-10188 as monotherapy in participants with relapsed/refractory (R/R) mature B-cell malignancies; in combination with zanubrutinib in participants with R/R follicular lymphoma (FL), R/R mantle cell lymphoma (MCL) or R/R diffuse large B-cell lymphoma (DLBCL); and in combination with tislelizumab in participants with advanced solid tumors.
Study Details
Timeline
Interventions
Administered as specified in the treatment arm
Administered as specified in the treatment arm
Administered as specified in the treatment arm